Second mobilization and collection of peripheral blood progenitor cells in healthy donors is associated with lower CD34(+) cell yields.
We have retrospectively evaluated the results of two cycles of mobilization and collection of peripheral blood progenitor cells (PBPC) from 46 healthy donors included in the Spanish National Donor Registry. Mobilization involved the administration of granulocyte colony-stimulating factor (G-CSF) at a median dose of 10 microg/kg per day, and apheresis was begun after the fourth dose of G-CSF in both cycles. The median interval between both mobilizations was 187 days (range, 7-1428 days). The incidence and types of side-effects were similar after both donations, with 25 and 26 donors developing some toxicity after the first and second donations, respectively. The median number of CD34(+) cells collected was higher after the first mobilization than after the second (5.15 versus 3.16 x 10(6)/kg, respectively; p = 0.05), and 29 donors yielded fewer CD34(+) cells after the second mobilization (p = 0.018). A lower proportion of donors yielded CD34(+) cell counts >4 x 10(6)/kg after the second cycle than after the first (52% versus 76%, respectively; p = 0.057). Our study shows that second rounds of PBPC collection from normal donors are well tolerated but are associated with a significantly reduced number of CD34(+) cells collected when the same mobilization scheme is used.
Spanish Group of Allogeneic Peripheral Blood Stem Cell Transplantation, La Fe University Hospital, 4600 Valencia, Spain. delarubia_jav@gva.es
Javier
J
De la Rubia
Cristina
C
Arbona
Consuelo
C
Del Cañizo
Rosario
R
Arrieta
Felipe
F
De Arriba
María J
MJ
Pascual
Isabel
I
Sanjuan
Miguel A
MA
Díaz
Salut
S
Brunet
Adrián
A
Alegre
Andrés
A
Insunza
Ildefonso
I
Espigado
Concha
C
Zamora
Javier
J
De la Serna
David
D
Serrano
Joan
J
Bargay
José
J
Petit
Dobleta
D
Martínez
Amparo
A
Verdeguer
José M
JM
Ribera
Carmen
C
Martínez
Luis
L
Benlloch
Miguel A
MA
Sanz
D000293:Adolescent; D000328:Adult; D000368:Aged; D015703:Antigens, CD / Q000097:blood; D018952:Antigens, CD34 / Q000097:blood*; D002648:Child; D005260:Female; D000069585:Filgrastim; D016179:Granulocyte Colony-Stimulating Factor / Q000627:therapeutic use; D019650:Hematopoietic Stem Cell Mobilization / Q000009:adverse effects / Q000379:methods*; D006412:Hematopoietic Stem Cells / Q000166:cytology*; D006454:Hemoglobins / Q000032:analysis; D006801:Humans; D000078224:Lenograstim; D007958:Leukocyte Count; D008297:Male; D008875:Middle Aged; D010976:Platelet Count; D011994:Recombinant Proteins / Q000627:therapeutic use; D012016:Reference Values; D012042:Registries; D012189:Retrospective Studies; D013030:Spain; D013997:Time Factors; D014019:Tissue Donors
D015703:Antigens, CD; D018952:Antigens, CD34; D006454:Hemoglobins; D011994:Recombinant Proteins; D016179:Granulocyte Colony-Stimulating Factor; D000078224:Lenograstim; D000069585:Filgrastim